Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults
Authors:
- Joseph DonovanJDJoseph Donovan
- Nguyen D. BangNBNguyen D. Bang
- Darma ImranDIDarma Imran
- Ho D.T. NghiaHNHo D.T. Nghia
- Erlina BurhanEBErlina Burhan
- Dau T.T. HuongDHDau T.T. Huong
- Nguyen T.T. HiepNHNguyen T.T. Hiep
- Lam H.B. NgocLNLam H.B. Ngoc
- Dang V. ThanhDTDang V. Thanh
- Nguyen T. ThanhNTNguyen T. Thanh
- Anna L.S. WardhaniAWAnna L.S. Wardhani
- Kartika MaharaniKMKartika Maharani
Top Cited Papers
Open Access
- 12 October 2023
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (15) , 1357-1367
Abstract
Adjunctive glucocorticoids are widely used to treat human immunodeficiency virus (HIV)-associated tuberculous meningitis despite limited data supporting their safety and efficacy. We conducted a double-blind, randomized, placebo-controlled trial involving HIV-positive adults (≥18 years of age) with tuberculous meningitis in Vietnam and Indonesia. Participants were randomly assigned to receive a 6-to-8-week tapering course of either dexamethasone or placebo in addition to 12 months of antituberculosis chemotherapy. The primary end point was death from any cause during the 12 months after randomization. A total of 520 adults were randomly assigned to receive either dexamethasone (263 participants) or placebo (257 participants). The median age was 36 years; 255 of 520 participants (49.0%) had never received antiretroviral therapy, and 251 of 484 participants (51.9%) with available data had a baseline CD4 count of 50 cells per cubic millimeter or less. Six participants withdrew from the trial, and five were lost to follow-up. During the 12 months of follow-up, death occurred in 116 of 263 participants (44.1%) in the dexamethasone group and in 126 of 257 participants (49.0%) in the placebo group (hazard ratio, 0.85; 95% confidence interval, 0.66 to 1.10; P = 0.22). Prespecified analyses did not reveal a subgroup that clearly benefited from dexamethasone. The incidence of secondary end-point events, including cases of immune reconstitution inflammatory syndrome during the first 6 months, was similar in the two trial groups. The numbers of participants with at least one serious adverse event were similar in the dexamethasone group (192 of 263 participants [73.0%]) and the placebo group (194 of 257 participants [75.5%]) (P = 0.52). Among HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone, as compared with placebo, did not confer a benefit with respect to survival or any secondary end point. (Funded by the Wellcome Trust; ACT HIV ClinicalTrials.gov number, NCT03092817.).Keywords
Funding Information
- Wellcome Trust (110179/Z/15/Z)
This publication has 25 references indexed in Scilit:
- Intensified Antituberculosis Therapy in Adults with Tuberculous MeningitisNew England Journal of Medicine, 2016
- Prednisolone andMycobacterium indicus praniiin Tuberculous PericarditisNew England Journal of Medicine, 2014
- Evaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous MeningitisJournal of Clinical Microbiology, 2014
- Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trialThe Lancet Infectious Diseases, 2013
- Frequency, Severity, and Prediction of Tuberculous Meningitis Immune Reconstitution Inflammatory SyndromeClinical Infectious Diseases, 2012
- Presentation and Outcome of Tuberculous Meningitis in a High HIV Prevalence SettingPLOS ONE, 2011
- Tuberculous meningitis: a uniform case definition for use in clinical researchThe Lancet Infectious Diseases, 2010
- British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and childrenJournal of Infection, 2009
- Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and AdultsNew England Journal of Medicine, 2004
- A Randomized, Double‐Blind, Placebo‐Controlled Trial of the Use of Prednisolone as an Adjunct to Treatment in HIV‐1–Associated Pleural TuberculosisThe Journal of Infectious Diseases, 2004